Follow-up Study of the RAI-Treated Hyperthyroid Patients
Previous studies of hyperthyroid patients suggest that they remain at increased risk of cardiovascular morbidity after restoring euthyroidism.
The study objective is to compare the rate and causes of hospitalization of hyperthyroid patients treated with radioactive iodine (RAI) with those of an age- and gender-matched reference population in a long-term follow-up study.
|Study Design:||Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective
|Official Title:||Follow-up Study of Hyperthyroid Patients Treated With RAI in 1965-2002: Morbidity in Long-Term Follow-up|
|Study Start Date:||January 1969|
|Study Completion Date:||December 2003|
A population-based cohort study was conducted among 2611 hyperthyroid patients treated with RAI between 1969 and 2002 in Tampere University Hospital, and among 2611 reference subjects. A reference group was randomly selected, with an age- and gender-matched control subject identified for each patient from the Population Register Centre. The control subject had to be alive at the time when the patient received the first RAI treatment.
The causes of hospitalization as well as the diagnosis and date of hospital admission were obtained from the nationwide Hospital Discharge Register (HILMO) maintained by the Research and Development Centre for Welfare and Health (STAKES) using a computerized record linkage, with the personal identification number as the key. The HILMO database covers all dates and causes of hospitalization (hospital admission requiring an overnight stay) of the Finnish citizens since January 1969. New events were analyzed as the main outcome, including only the first hospitalization due to a given indication. The special focus was on the cardiovascular morbidity.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00471458
|Tampere University Hospital, Department of Internal Medicine|
|Tampere, Finland, 33521|
|Principal Investigator:||Saara Metso, MD||Tampere University Hospital, Department of Internal Medicine, FIN-33521 Tampere, Finland|
|Study Director:||Pia Jaatinen, MD, PhD||Medical School, University of Tampere, Tampere, FINLAND|
|Study Director:||Jorma Salmi, MD, PhD||Tampere University Hopsital, Department of Internal Medicine, FIN-33521 TAMPERE, FINLAND|